Bayesian inference for the lead time in periodic cancer screening

Biometrics

Volumn 63, Issue 3, 2007, Pages 873-880

  Wu, Dongfeng ^a   Rosner, Gary L ^b   Broemeling, Lyle D ^b  

^a MISSISSIPPI STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Breast cancer; Early detection; Lead time; Periodic screening exams; Sensitivity; Sojourn time; Transition probability

Indexed keywords

BAYESIAN NETWORKS; CHEMICAL DETECTION; DISEASES; INFERENCE ENGINES; PROBABILITY DISTRIBUTIONS;

BREAST CANCER; BREAST CANCER SCREENING; CANCER SCREENING; EARLY DETECTION; LEADTIME; PERIODIC SCREENING EXAM; SCREENING PROGRAMS; SENSITIVITY; SOJOURN TIME; TRANSITION PROBABILITIES;

DIAGNOSIS;

BAYESIAN ANALYSIS; CANCER; PROBABILITY; TEMPORAL DISTRIBUTION;

ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; DATA ANALYSIS; FREQUENCY ANALYSIS; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INFORMATION PROCESSING; MATHEMATICAL MODEL; ONSET AGE; PROBABILITY; SIMULATION; STATISTICAL ANALYSIS; STATISTICAL PARAMETERS; TIME SERIES ANALYSIS; UNITED STATES; VARIANCE;

NEW YORK [UNITED STATES]; NORTH AMERICA; UNITED STATES;

EID: 34548382254     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2006.00732.x     Document Type: Article

References (24)

1. Baker, S. G., Erwin, D., Kramer, B. S., and Prorok, P. C. (2003). Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. BMC Medical Research Methodology 3, 4.
2. Baker, S. G., Kramer, B. S., McIntosh, M., Patterson, B. H., Shyr, Y., and Skates, S. (2006). Evaluating markers for the early detection of cancer: Overview of study designs and methods. Clinical Trials 3, 43 56.
3. Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., and Feuer, E. (2005). Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine 353, 1784 1792.
4. Chen, H. H., Duffy, S. W., Tabar, L., and Day, N. E. (1997). Markov chain models for progression of breast cancer part II: Prediction of outcomes for different screening regimes. Journal of Epidemiology and Biostatistics 2, 25 35.
5. Dwyer, A. J., Prewitt, J. M. S., Ecker, J. G., and Plunkett, J. (1983). Use of the hazard rate to schedule follow-up exams efficiently: An optimization approach to patient management. Medical Decision Making 3, 229 244.
6. Eddy, D. M. (1980). Screening for Cancer: Theory, Analysis and Design. Englewood Cliffs, New Jersey : Prentice Hall.
7. Flanders, W. D. and Longini, I. M. (1990). Estimating benefits of screening from observational cohort studies. Statistics in Medicine 9, 969 980.
8. Gilks, W. R., Richardson, S., and Spiegelhalter, D. J. (1996). Markov Chain Monte Carlo in Practice. Boca Raton, Florida : Chapman & Hall/CRC.
9. Kafadar, K. and Prorok, P. C. (1994). A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials. Statistics in Medicine 13, 569 586.
10. Kafadar, K. and Prorok, P. C. (1996). Computer simulation of randomized cancer screening trials to compare methods of estimating lead time and benefit time. Computational Statistics and Data Analysis 23, 263 291.
11. Kafadar, K. and Prorok, P. C. (2003). Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials. Statistics in Medicine 22, 83 111.
12. Kafadar, K., Prorok, P. C., and Smith, P. J. (1998). An estimate of the variance of estimators for lead time and screening benefit time in randomized cancer screening trials. Biometrical Journal 40, 801 821.
13. National Institutes of Health (1997). Breast cancer screening for women ages 40-49. NIH Publication No. 103, January 21-23, 1997, Bethesda, Maryland.
14. National Institutes of Health (2000). What you need to know about breast cancer. NIH Publication No. 00-1556, 12/12/2000, Bethesda, Maryland.
15. Parmigiani, G. (2002). Modeling in Medical Decision Making: A Bayesian Approach. Chichester, U.K. : Wiley.
16. Prorok, P. C. (1982). Bounded recurrence times and lead time in the design of a repetitive screening program. Journal of Applied Probability 19, 10 19.
17. Shapiro, S., Venet, W., Strax, P., and Venet, L. (1988). Periodic Screening for Breast Cancer. The Health Insurance Plan Project and its Sequelae, 1963-1986. Baltimore, Maryland : The Johns Hopkins University Press.
18. Straatman, H., Peer, P. G. M., and Verbeek, A. L. M. (1997). Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group. Biometrics 53, 217 229.
19. Walter, S. D. and Day, N. E. (1983). Estimation of the duration of a preclinical disease state using screening data. American Journal of Epidemiology 118, 856 886.
20. Wu, D., Rosner, G., and Broemeling, L. (2005). MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening. Biometrics 61, 1056 1063.
21. Xu, J. and Prorok, P. C. (1995). Non-parametric estimation of the post-lead-time survival distribution of screen-detected cancer cases. Statistics in Medicine 14, 2715 2725.
22. Xu, J., Fagerstrom, R. M., and Prorok, P. C. (1999). Estimation of post-lead-time survival under dependence between lead-time and post-lead-time survival. Statistics in Medicine 18, 155 162.
23. Zelen, M. (1993). Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening. Biometrika 80, 279 293.
24. Zelen, M. and Feinleib, M. (1969). On the theory of screening for chronic diseases. Biometrika 56, 601 614.